Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Kricorian

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Pediatric Dermatology|February 22, 2019
A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis populationAmy S Paller, Jennifer Schenfeld, Neil A Accortt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 9, 2020
ReplyPhilip J Mease, David H Collier, Gregory Kricorian, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanerceptJerry Bagel, Charles Lynde, Stephen Tyring, et al.
The Journal of Dermatological Treatment|June 7, 2012
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan populationBenjamin Chastek, Kathleen M Fox, Crystal Watson, et al.
Journal of Drugs in Dermatology : JDD|April 10, 2020
Evaluation of Patient-Reported Outcomes With Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With ApremilastJerry Bagel, Bradley S Stolshek, Yue Yang, et al.
European Journal of Dermatology : EJD|February 27, 2010
Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasisIan Landells, Amy S Paller, David Pariser, et al.
Journal of the American Academy of Dermatology|September 14, 2010
Intermittent etanercept therapy in pediatric patients with psoriasisElaine C Siegfried, Lawrence F Eichenfield, Amy S Paller, et al.
ACR Open Rheumatology|June 25, 2023
Real-World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Jacqueline O'Brien, Nicole Middaugh, et al.
Journal of the American Academy of Dermatology|July 17, 2010
Subgroup analyses of etanercept in pediatric patients with psoriasisAmy S Paller, Lawrence F Eichenfield, Richard G Langley, et al.
The Journal of Investigative Dermatology|June 8, 2012
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsDavid A Martin, Jennifer E Towne, Gregory Kricorian, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Pediatric Dermatology|February 22, 2019
A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis populationAmy S Paller, Jennifer Schenfeld, Neil A Accortt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 9, 2020
ReplyPhilip J Mease, David H Collier, Gregory Kricorian, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanerceptJerry Bagel, Charles Lynde, Stephen Tyring, et al.
The Journal of Dermatological Treatment|June 7, 2012
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan populationBenjamin Chastek, Kathleen M Fox, Crystal Watson, et al.
Journal of Drugs in Dermatology : JDD|April 10, 2020
Evaluation of Patient-Reported Outcomes With Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With ApremilastJerry Bagel, Bradley S Stolshek, Yue Yang, et al.
European Journal of Dermatology : EJD|February 27, 2010
Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasisIan Landells, Amy S Paller, David Pariser, et al.
Journal of the American Academy of Dermatology|September 14, 2010
Intermittent etanercept therapy in pediatric patients with psoriasisElaine C Siegfried, Lawrence F Eichenfield, Amy S Paller, et al.
ACR Open Rheumatology|June 25, 2023
Real-World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Jacqueline O'Brien, Nicole Middaugh, et al.
Journal of the American Academy of Dermatology|July 17, 2010
Subgroup analyses of etanercept in pediatric patients with psoriasisAmy S Paller, Lawrence F Eichenfield, Richard G Langley, et al.
The Journal of Investigative Dermatology|June 8, 2012
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsDavid A Martin, Jennifer E Towne, Gregory Kricorian, et al.
Pageof 3